Accounts Receivable, after Allowance for Credit Loss, Current of Iterum Therapeutics plc for 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Iterum Therapeutics plc quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate for 30 Sep 2025.
  • Iterum Therapeutics plc Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Sep 2025 was $448,000.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)

Iterum Therapeutics plc Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $448,000 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.